Anesthesia Knowledge Test-6 (AKT-6) Practice Exam 2026 - Free Anesthesia Practice Questions and Study Guide

The least affected neuromuscular blockade (NMB) agent by liver or renal dysfunction is rapacuronium. This is primarily due to its unique pharmacokinetic properties. Rapacuronium is metabolized primarily via non-specific plasma esterases rather than through hepatic or renal pathways. As a result, patients with liver or kidney impairments do not experience significant alterations in the drug's metabolism or clearance.

This characteristic makes rapacuronium a safer choice in patients who may have compromised liver or renal function, as it reduces the risk of prolonged neuromuscular blockade due to accumulation of the drug. Other agents listed may have a degree of dependence on liver or renal function for their metabolism or clearance, which could lead to altered pharmacodynamics in affected patients. Thus, rapacuronium's distinctive metabolic pathway keeps its effectiveness and safety profile stable, regardless of the patient's hepatic or renal status.